Solid form of 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide methanesulfonate

Abstract

The present invention relates to a solid form of 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamidomethanesulfonic acid (INN: belmosudil mesylate) and a process for its preparation. Furthermore, the present invention relates to a pharmaceutical composition comprising the solid form of the present invention and at least one pharma- ceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament for the treatment and / or prevention of autoimmune diseases, in particular graft-versus-host disease (GvHD) and systemic sclerosis.

Description

[Technical field]

[0001] The present invention relates to a solid form of 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamidomethanesulfonic acid (INN: belmosudil mesylate) and a process for its preparation. Furthermore, the present invention relates to a pharmaceutical composition comprising the solid form of the present invention and at least one pharma- ceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament for the treatment and / or prevention of autoimmune diseases, in particular graft-versus-host disease (GvHD) and systemic sclerosis. [Background technology]

[0002] Graft-versus-host disease is a complication that can occur in patients who receive transplants. In this disease, transplanted cells recognize the patient's body as "foreign" and attack the patient's organs, such as the stomach, intestines, skin, and liver, resulting in organ damage. The disease can occur soon after transplantation or later, in which case more organs can be affected. Graft-versus-host disease is a severe and life-threatening disease with a high mortality rate.

[0003] Belmosudil blocks an enzyme called Rho-associated protein kinase 2 (ROCK2), which plays a role in the inflammation that occurs in graft-versus-host disease, leading to organ damage. By blocking this enzyme, Belmosudil is expected to help reduce inflammation, thereby alleviating the symptoms of the condition.

[0004] The chemical name of Belmosudil is 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide and can be represented by the following chemical structure according to formula (A).

[0005] [ka]

[0006] Belmosudil and its preparation are disclosed in WO2006 / 105081A1. In the last step of Example 82, crude belmosudil was purified using preparative HPLC. Example 92 of WO2008 / 054599A1 discloses the preparation of belmosudil trifluoroacetate. The preparation of belmosudil hydrochloride is disclosed in Example 5 of WO2014 / 055999A1.

[0007] Different solid forms of active pharmaceutical ingredients (API) often have different properties. The difference in physicochemical properties of solid forms can play an important role in improving pharmaceutical compositions, for example, pharmaceutical formulations with improved dissolution profile and bioavailability, or improved stability or shelf life, can be made available by improving the solid form of the active pharmaceutical ingredient. Also, the processing or handling of the active pharmaceutical ingredient during the formulation process can be improved. Thus, new solid forms of the active pharmaceutical ingredient can have desirable processing properties. They can be easier to handle, more suitable for storage, and / or allow better purification compared to previously known solid forms.

[0008] Belmosudil trifluoroacetate of WO2008 / 054599A1 and belmosudil hydrochloride of WO2014 / 055999A1 have certain drawbacks that impair their use in pharmaceutical compositions, especially in solid dosage forms.For example, they show low crystallinity (see Figures 15 and 16 below) and significantly interact with water vapor when in contact with moisture (see Comparative Example 1 herein).Belmosudil hydrochloride takes up significantly more water with increasing relative humidity levels, while belmosudil trifluoroacetate contains unacceptably high levels of residual solvents that are partially released and exchanged for water when in contact with moisture. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] International Publication No. 2006 / 105081 [Patent Document 2] International Publication No. 2008 / 054599 [Patent Document 3] International Publication No. 2014 / 055999 Summary of the Invention [Problem to be solved by the invention]

[0010] Therefore, there is a need to provide a solid form of belmosudil having improved physicochemical properties. [Means for solving the problem]

[0011] The present invention provides crystalline forms of belmosudil mesylate, hereinafter also referred to as "Form I", "Form II", "Form HyA" and "Form HyB", as well as an amorphous form of belmosudil mesylate.

[0012] The solid forms of the present invention have one or more advantageous properties selected from the group consisting of chemical stability, physical stability, melting point, hygroscopicity, solubility, dissolution, morphology, crystallinity, flowability, bulk density, compressibility and wettability.

[0013] In particular, Form I, Form II, Form HyA and Form HyB of belmosudil mesylate exhibit high crystallinity (see Figures 1-4 and 6). In addition, Form I and Form II of anhydrous belmosudil mesylate of the present invention take up less than 2% water by weight as measured by gravimetric moisture sorption in the range of relative humidity 0-80% and temperature (25±0.1°C), and therefore can be designated as being only slightly hygroscopic. Furthermore, both forms of anhydrous belmosudil mesylate of the present invention are stable to temperature stress (see Examples 7 and 8 and Figures 7, 8, 11 and 12 below).

[0014] <abbreviation> PXRD Powder X-ray diffraction diagram FTIR Fourier Transform Infrared DSC Differential Scanning Calorimetry TGA thermogravimetric analysis GMS Gravimetric Moisture Sorption w-% Weight percent RH Relative Humidity TFA Trifluoroacetic acid

[0015] <Definition> In the context of the present invention, unless otherwise stated, the following definitions have the meanings indicated.

[0016] As used herein, the term "measured at a temperature in the range of 20-30°C" refers to measurement under standard conditions. Typically, standard conditions refer to a temperature in the range of 20-30°C, i.e., room temperature. Standard conditions may refer to a temperature of about 22°C. Typically, standard conditions may further refer to measurement at 20-60% RH, preferably 30-50% RH, more preferably 40% RH.

[0017] As used herein, the term "room temperature" refers to a temperature in the range of 20-30°C.

[0018] As used herein, the term "reflection" in relation to powder X-ray diffraction means a peak in the X-ray diffraction diagram caused at a certain diffraction angle (Bragg angle) by structural interference from X-rays scattered by parallel planes of atoms in a solid material, the peaks being distributed in a regular and repeating pattern with long-range positional order. Such solid materials are classified as crystalline materials, whereas amorphous materials are defined as solid materials that lack long-range order and exhibit only short-range order, thus resulting in broad scattering. According to the literature, long-range order extends, for example, to about 100-1000 atoms, whereas short-range order extends to only a few atoms (see "Fundamentals of Powder Diffraction and Structural Characterization of Materials" by Vitalij K. Pecharsky and Peter Y. Zavalij, Kluwer Academic Publishers, 2003, p. 3).

[0019] The term "essentially the same" in reference to powder X-ray diffraction means that variations in reflection position and relative intensity of reflections are taken into account. For example, typical accuracy of 2θ values ​​is in the range of ±0.2°2θ, preferably in the range of ±0.1°2θ. Thus, for example, a reflection that normally appears at 7.1°2θ may appear between 6.9°-7.3°2θ, preferably between 7.0°-7.2°2θ, on most X-ray diffractometers under standard conditions. Furthermore, the skilled artisan will understand that the relative reflection intensity indicates instrument-to-instrument variability as well as variability due to crystallinity, preferred orientation, particle size, sample preparation, and other factors known to those skilled in the art, and should be interpreted only as a qualitative measure.

[0020] The solid form of belmosudil mesylate of the present invention may be referred to herein as being characterized by the graphical data "shown in the figure". Such data includes, for example, powder X-ray diffraction. Those skilled in the art will understand that factors such as instrument type, response variation, and sample orientation, sample concentration, and sample purity variation may cause small variations in such data when presented in graphical form, such as variations in exact reflection position and intensity. However, it is within the knowledge of those skilled in the art to compare the graphical data in the figures herein with the graphical data generated for another or unknown solid form, and to confirm that the two sets of graphical data relate to the same crystalline form.

[0021] As used herein, the term "solid form" refers to any crystalline and / or amorphous phase of a compound.

[0022] As used herein, the term "amorphous" refers to a solid form of a compound that is not crystalline. Amorphous compounds do not have long range order and do not exhibit a distinct X-ray diffraction pattern with reflections.

[0023] As used herein, the term "anhydrous" refers to a crystalline solid in which water is not associated within or accommodated by the crystal structure.

[0024] As used herein with respect to a crystalline or amorphous form of belmosudil mesylate, "predetermined amount" refers to the initial amount of the form calculated as belmosudil used to prepare a pharmaceutical composition having the desired dosage strength of belmosudil.

[0025] As used herein with respect to a crystalline or amorphous form of belmosudil mesylate, the term "effective amount" encompasses the amount of the form, calculated as belmosudil, that elicits the desired therapeutic and / or prophylactic effect.

[0026] As used herein, the term "about" means within a statistically meaningful range of values. Such ranges may be within an order of magnitude, typically within 10%, more typically within 5%, even more typically within 1%, and most typically within 0.1% of the indicated value or range. Sometimes such ranges may be within the experimental error typical of the standard method used to measure and / or determine a given value or range.

[0027] As used herein, the term "pharmaceutical acceptable excipient" refers to a substance that does not exhibit significant pharmacological activity at a given dose and that is added to a pharmaceutical composition in addition to an active pharmaceutical ingredient. An excipient may function as, among other things, a vehicle, a diluent, a release agent, a disintegrant, a dissolution modifier, an absorption enhancer, a stabilizer, or a manufacturing aid.

[0028] As used herein, the term "filler" refers to a substance used to dilute an active pharmaceutical ingredient prior to delivery. Fillers may also function as stabilizers or disintegrants.

[0029] As used herein, the term "disintegrant" refers to a substance that, when added to a solid pharmaceutical composition, promotes breakup or disintegration after administration, allowing the release of the active pharmaceutical ingredient as efficiently as possible, thereby allowing for its rapid dissolution.

[0030] As used herein, the term "lubricant" refers to a substance added to a powder blend to prevent the compressed powder mass from sticking to equipment during the tabletting or encapsulation process.

[0031] As used herein, the term "binder" refers to a substance that binds an active pharmaceutical ingredient and a pharma-ceutically acceptable excipient together to maintain them as cohesive and discrete parts.

[0032] As used herein, the term "glidant" refers to substances used in tablet and capsule formulations to improve flow characteristics during tablet compression and to provide an anti-caking effect. [Brief description of the drawings]

[0033] [Figure 1] 1 shows a representative PXRD of belmosudil mesylate Form I according to the present invention, where the x-axis shows the scattering angle in 2θ° and the y-axis shows the intensity of the scattered X-ray beam in photon counts detected. [Diagram 2] 1 shows a representative PXRD of belmosudil mesylate Form II according to the present invention, where the x-axis shows the scattering angle in 2θ° and the y-axis shows the intensity of the scattered X-ray beam in photon counts detected. [Diagram 3] 1 shows a representative PXRD of belmosudil mesylate form HyA according to the present invention, where the x-axis shows the scattering angle in 2θ° and the y-axis shows the intensity of the scattered X-ray beam in photon counts detected. [Figure 4] 1 shows a representative PXRD of belmosudil mesylate form HyB according to the present invention, where the x-axis shows the scattering angle in 2θ° and the y-axis shows the intensity of the scattered X-ray beam in photon counts detected. [Diagram 5] Figure 1 shows a representative PXRD of amorphous belosudil mesylate, where the x-axis shows the scattering angle in 2θ° and the y-axis shows the intensity of the scattered X-ray beam in photon counts detected. [Figure 6]PXRD comparison of belmosudil mesylate form I, form II, form HyA and form HyB (top to bottom). The x-axis shows the scattering angle in 2θ°. The PXRD was shifted along the y-axis to separate the diffractograms for clarity. [Figure 7] 1 shows a representative DSC curve of belmosudil mesylate Form I according to the present invention, where the x-axis shows the temperature in degrees Celsius (° C.) and the y-axis shows the heat flow in watts per gram (W / g) at which the endothermic peak rises. [Figure 8] 1 shows a representative DSC curve of belmosudil mesylate Form II according to the present invention, where the x-axis shows the temperature in degrees Celsius (° C.) and the y-axis shows the heat flow in watts per gram (W / g) at which the endothermic peak rises. [Figure 9] 1 shows a representative DSC curve of belmosudil mesylate form HyA according to the present invention, where the x-axis shows temperature in degrees Celsius (° C.) and the y-axis shows the heat flow in watts per gram (W / g) at which the endothermic peak rises. [Figure 10] 1 shows a representative DSC curve of belmosudil mesylate form HyB according to the present invention, where the x-axis shows the temperature in degrees Celsius (° C.) and the y-axis shows the heat flow in watts per gram (W / g) at which the endothermic peak rises. [Figure 11] 1 shows a representative TGA curve of the present invention's belmosudil mesylate Form I. The x-axis shows the temperature in degrees Celsius (° C.) and the y-axis shows the mass (loss) of the sample in weight percent (w-%). [Figure 12] 1 shows a representative TGA curve of belmosudil mesylate Form II of the present invention, where the x-axis shows temperature in degrees Celsius (° C.) and the y-axis shows the mass (loss) of the sample in weight percent (w-%). [Figure 13] 1 shows a representative TGA curve of belmosudil mesylate form HyA of the present invention, where the x-axis shows temperature in degrees Celsius (° C.) and the y-axis shows the mass (loss) of the sample in weight percent (w-%). [Figure 14] 1 shows a representative TGA curve of belmosudil mesylate form HyB of the present invention, where the x-axis shows temperature in degrees Celsius (° C.) and the y-axis shows the mass (loss) of the sample in weight percent (w-%). [Figure 15]1 shows a representative PXRD of belmosudil HCl salt prepared according to the procedure disclosed in Example 5 of WO2014 / 055999A1, where the x-axis shows the scattering angle in 2θ° and the y-axis shows the intensity of the scattered X-ray beam in photon counts detected. [Figure 16] 1 shows a representative PXRD of belmosudil TFA salt prepared according to the procedure disclosed in Example 92 of WO2008 / 054599A1, where the x-axis shows the scattering angle in 2θ° and the y-axis shows the intensity of the scattered X-ray beam in photon counts detected. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] The present invention relates to solid forms of belmosdil mesylate, including crystalline belmosdil mesylate and amorphous belmosdil mesylate.

[0035] Thus, in a first aspect, the present invention relates to a crystalline belmosudil mesylate conforming to the chemical structure shown in formula (B).

[0036] [ka] In the formula, n is in the range of 0.8 to 1.2, preferably 0.9 to 1.1, even more preferably 0.95 to 1.05, and most preferably n is 1.0.

[0037] In particular, the present invention relates to crystalline forms of belmosudil mesylate, also referred to herein as "Form I", "Form II", "Form HyA" and "Form HyB". The crystalline forms of belmosudil mesylate of the present invention can be characterized by analytical methods well known in the field of pharmaceutical industry for characterizing solids. Such methods include, but are not limited to, powder X-ray diffraction, single X-ray diffraction, FTIR spectroscopy, DSC, TGA and GMS. The crystalline forms of the present invention can be characterized by one of the aforementioned analytical methods or by combining two or more of them. In particular, the crystalline forms of belmosudil mesylate of the present invention can be characterized by any one of the following embodiments or by combining two or more of the following embodiments.

[0038] <Crystal form I of belmosudil mesylate> In one embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form I), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0039] (7.1±0.2)°, (8.4±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (20.3±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (17.3±0.2)°, (20.3±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (13.4±0.2)°, (17.3±0.2)°, (20.3±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (13.4±0.2)°, (17.3±0.2)°, (20.3±0.2)°, (23.6±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (13.4±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (23.6±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (13.4±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (23.6±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (13.4±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (21.6±0.2)°, (23.6±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (13.4±0.2)°, (15.7±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (21.6±0.2)°, (23.6±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (13.4±0.2)°, (14.5±0.2)°, (15.7±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (21.6±0.2)°, (23.6±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (12.5±0.2)°, (13.4±0.2)°, (14.5±0.2)°, (15.7±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (21.6±0.2)°, (23.6±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (12.5±0.2)°, (13.4±0.2)°, (14.5±0.2)°, (15.7±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (21.6±0.2)°, (23.6±0.2)°, (25.1±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (12.5±0.2)°, (13.4±0.2)°, (14.5±0.2)°, (15.7±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (21.6±0.2)°, (22.2±0.2)°, (23.6±0.2)°, (25.1±0.2)° and (25.6±0.2)° or (7.1±0.2)°, (8.4±0.2)°, (12.5±0.2)°, (13.4±0.2)°, (14.5±0.2)°, (15.7±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (21.0±0.2)°, (21.6±0.2)°, (22.2±0.2)°, (23.6±0.2)°, (25.1±0.2)° and (25.6±0.2)°

[0040] In another embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form I), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0041] (7.1±0.1)°, (8.4±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (20.3±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (17.3±0.1)°, (20.3±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (13.4±0.1)°, (17.3±0.1)°, (20.3±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (13.4±0.1)°, (17.3±0.1)°, (20.3±0.1)°, (23.6±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (13.4±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (23.6±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (13.4±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (23.6±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (13.4±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (21.6±0.1)°, (23.6±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (13.4±0.1)°, (15.7±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (21.6±0.1)°, (23.6±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (13.4±0.1)°, (14.5±0.1)°, (15.7±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (21.6±0.1)°, (23.6±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (12.5±0.1)°, (13.4±0.1)°, (14.5±0.1)°, (15.7±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (21.6±0.1)°, (23.6±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (12.5±0.1)°, (13.4±0.1)°, (14.5±0.1)°, (15.7±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (21.6±0.1)°, (23.6±0.1)°, (25.1±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (12.5±0.1)°, (13.4±0.1)°, (14.5±0.1)°, (15.7±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (21.6±0.1)°, (22.2±0.1)°, (23.6±0.1)°, (25.1±0.1)° and (25.6±0.1)° or (7.1±0.1)°, (8.4±0.1)°, (12.5±0.1)°, (13.4±0.1)°, (14.5±0.1)°, (15.7±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (21.0±0.1)°, (21.6±0.1)°, (22.2±0.1)°, (23.6±0.1)°, (25.1±0.1)° and (25.6±0.1)°

[0042] In a further embodiment, the present invention relates to a Cu-Kα ion exchanger having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form I), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0043] (7.1±0.2)°, (13.4±0.2)°, (16.8±0.2)°, (17.3±0.2)°, (19.5±0.2)°, (20.3±0.2)°, (21.6±0.2)°, (23.6±0.2)°, (25.1±0.2)° and (25.6±0.2)°

[0044] In yet another embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form I), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0045] (7.1±0.1)°, (13.4±0.1)°, (16.8±0.1)°, (17.3±0.1)°, (19.5±0.1)°, (20.3±0.1)°, (21.6±0.1)°, (23.6±0.1)°, (25.1±0.1)° and (25.6±0.1)°

[0046] In yet another embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form I), characterized in that it has essentially the same PXRD as shown in FIG. 1 of the present invention, when measured using radioactive materials.

[0047] In another embodiment, the present invention relates to a crystalline form of belmosudil mesylate (Form I), characterized in that it has a DSC curve comprising an endothermic peak, preferably a single endothermic peak, with onset at a temperature of about (264±5)°C, preferably about (264±3)°C, more preferably about (264±1)°C, e.g. 263.9°C, when measured at a heating rate of 10 K / min.

[0048] In a further embodiment, the present invention relates to a crystalline form of belmosudil mesylate (Form I) as defined in any one of the above embodiments, characterized in that it is anhydrous.

[0049] <Crystal Form II of Belmosudil Mesylate> In one embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form II), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0050] (7.3±0.2)°, (9.4±0.2)° and (16.6±0.2)° or (6.9±0.2)°, (7.3±0.2)°, (9.4±0.2)° and (16.6±0.2)° or (6.9±0.2)°, (7.3±0.2)°, (9.4±0.2)°, (16.6±0.2)° and (25.9±0.2)° or (6.9±0.2)°, (7.3±0.2)°, (9.4±0.2)°, (16.6±0.2)°, (17.4±0.2)° and (25.9±0.2)° or (6.9±0.2)°, (7.3±0.2)°, (9.4±0.2)°, (14.6±0.2)°, (16.6±0.2)°, (17.4±0.2)° and (25.9±0.2)° or (6.9±0.2)°, (7.3±0.2)°, (9.4±0.2)°, (14.6±0.2)°, (16.6±0.2)°, (17.4±0.2)°, (19.6±0.2)° and (25.9±0.2)° or (6.9±0.2)°, (7.3±0.2)°, (9.4±0.2)°, (13.7±0.2)°, (14.6±0.2)°, (16.6±0.2)°, (17.4±0.2)°, (19.6±0.2)° and (25.9±0.2)° or (6.9±0.2)°, (7.3±0.2)°, (9.4±0.2)°, (12.8±0.2)°, (13.7±0.2)°, (14.6±0.2)°, (16.6±0.2)°, (17.4±0.2)°, (19.6±0.2)° and (25.9±0.2)°

[0051] In another embodiment, the present invention relates to a Cu-Kα1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form II), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0052] (7.3±0.1)°, (9.4±0.1)° and (16.6±0.1)° or (6.9±0.1)°, (7.3±0.1)°, (9.4±0.1)° and (16.6±0.1)° or (6.9±0.1)°, (7.3±0.1)°, (9.4±0.1)°, (16.6±0.1)° and (25.9±0.1)° or (6.9±0.1)°, (7.3±0.1)°, (9.4±0.1)°, (16.6±0.1)°, (17.4±0.1)° and (25.9±0.1)° or (6.9±0.1)°, (7.3±0.1)°, (9.4±0.1)°, (14.6±0.1)°, (16.6±0.1)°, (17.4±0.1)° and (25.9±0.1)° or (6.9±0.1)°, (7.3±0.1)°, (9.4±0.1)°, (14.6±0.1)°, (16.6±0.1)°, (17.4±0.1)°, (19.6±0.1)° and (25.9±0.1)° or (6.9±0.1)°, (7.3±0.1)°, (9.4±0.1)°, (13.7±0.1)°, (14.6±0.1)°, (16.6±0.1)°, (17.4±0.1)°, (19.6±0.1)° and (25.9±0.1)° or (6.9±0.1)°, (7.3±0.1)°, (9.4±0.1)°, (12.8±0.1)°, (13.7±0.1)°, (14.6±0.1)°, (16.6±0.1)°, (17.4±0.1)°, (19.6±0.1)° and (25.9±0.1)°

[0053] In a further embodiment, the present invention relates to a Cu-Kα ion exchanger having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2The present invention relates to a crystalline form of belmosudil mesylate (Form II), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0054] (6.9±0.2)°, (7.3±0.2)°, (12.8±0.2)°, (13.7±0.2)°, (14.6±0.2)°, (16.6±0.2)°, (17.4±0.2)°, (19.6±0.2)°, (21.0±0.2)° and (25.9±0.2)°

[0055] In yet another embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form II), characterized in that it has a PXRD containing reflections at 2θ angles of 0.01 to 0.01, when measured using radiation.

[0056] (6.9±0.1)°, (7.3±0.1)°, (12.8±0.1)°, (13.7±0.1)°, (14.6±0.1)°, (16.6±0.1)°, (17.4±0.1)°, (19.6±0.1)°, (21.0±0.1)° and (25.9±0.1)°

[0057] In yet another embodiment, the present invention provides a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (Form II), characterized in that it has essentially the same PXRD as shown in FIG. 2 of the present invention, when measured using radioactive material.

[0058] In another embodiment, the present invention relates to a crystalline form of belmosudil mesylate (Form II), characterized in that it has a DSC curve comprising an endothermic peak, preferably a single endothermic peak, with onset at a temperature of about (248±5)°C, preferably about (248±3)°C, more preferably about (248±1)°C, e.g. 247.5°C, when measured at a heating rate of 10 K / min.

[0059] In a further embodiment, the present invention relates to a crystalline form of belmosudil mesylate (Form II) as defined in any one of the above embodiments, characterized in that it is anhydrous.

[0060] <Crystal form HyA of belmosudil mesylate> In one embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyA), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0061] (6.3±0.2)°, (12.7±0.2)° and (14.5±0.2)° or (6.3±0.2)°, (12.7±0.2)°, (14.5±0.2)° and (19.0±0.2)° or (6.3±0.2)°, (7.9±0.2)°, (12.7±0.2)°, (14.5±0.2)° and (19.0±0.2)° or (6.3±0.2)°, (7.9±0.2)°, (10.0±0.2)°, (12.7±0.2)°, (14.5±0.2)° and (19.0±0.2)° or (6.3±0.2)°, (7.9±0.2)°, (10.0±0.2)°, (12.7±0.2)°, (14.5±0.2)°, (19.0±0.2)° and (26.5±0.2)° or (6.3±0.2)°, (7.9±0.2)°, (10.0±0.2)°, (12.7±0.2)°, (14.5±0.2)°, (19.0±0.2)°, (26.5±0.2)° and (27.4±0.2)° or (6.3±0.2)°, (7.9±0.2)°, (10.0±0.2)°, (12.7±0.2)°, (14.5±0.2)°, (15.8±0.2)°, (19.0±0.2)°, (26.5±0.2)° and (27.4±0.2)° or (6.3±0.2)°, (7.9±0.2)°, (10.0±0.2)°, (12.7±0.2)°, (13.6±0.2)°, (14.5±0.2)°, (15.8±0.2)°, (19.0±0.2)°, (26.5±0.2)° and (27.4±0.2)°

[0062] In another embodiment, the present invention relates to a Cu-Kα 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyA), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0063] (6.3±0.1)°, (12.7±0.1)° and (14.5±0.1)° or (6.3±0.1)°, (12.7±0.1)°, (14.5±0.1)° and (19.0±0.1)° or (6.3±0.1)°, (7.9±0.1)°, (12.7±0.1)°, (14.5±0.1)° and (19.0±0.1)° or (6.3±0.1)°, (7.9±0.1)°, (10.0±0.1)°, (12.7±0.1)°, (14.5±0.1)° and (19.0±0.1)° or (6.3±0.1)°, (7.9±0.1)°, (10.0±0.1)°, (12.7±0.1)°, (14.5±0.1)°, (19.0±0.1)° and (26.5±0.1)° or (6.3±0.1)°, (7.9±0.1)°, (10.0±0.1)°, (12.7±0.1)°, (14.5±0.1)°, (19.0±0.1)°, (26.5±0.1)° and (27.4±0.1)° or (6.3±0.1)°, (7.9±0.1)°, (10.0±0.1)°, (12.7±0.1)°, (14.5±0.1)°, (15.8±0.1)°, (19.0±0.1)°, (26.5±0.1)° and (27.4±0.1)° or (6.3±0.1)°, (7.9±0.1)°, (10.0±0.1)°, (12.7±0.1)°, (13.6±0.1)°, (14.5±0.1)°, (15.8±0.1)°, (19.0±0.1)°, (26.5±0.1)° and (27.4±0.1)°

[0064] In a further embodiment, the present invention relates to a Cu-Kα ion exchanger having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyA), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0065] (6.3±0.2)°, (12.7±0.2)°, (13.6±0.2)°, (15.8±0.2)°, (16.0±0.2)°, (19.0±0.2)°, (25.2±0.2)°, (25.4±0.2)°, (26.5±0.2)° and (27.4±0.2)°

[0066] In yet another embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyA), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0067] (6.3±0.1)°, (12.7±0.1)°, (13.6±0.1)°, (15.8±0.1)°, (16.0±0.1)°, (19.0±0.1)°, (25.2±0.1)°, (25.4±0.1)°, (26.5±0.1)° and (27.4±0.1)°

[0068] In yet another embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyA), characterized in that it has essentially the same PXRD as shown in FIG. 3 of the present invention, when measured using radioactive material.

[0069] In another embodiment, the present invention relates to a crystalline form of belmosudil mesylate (form HyA), characterized in that it has a DSC curve comprising an endothermic peak with onset at a temperature of about (76±5)°C, preferably about (76±3)°C, more preferably about (76±1)°C, e.g. 76.3°C, when measured at a heating rate of 10 K / min.

[0070] In a further embodiment, the present invention relates to a crystalline form of belmosudil mesylate (form HyA) as defined in any one of the above embodiments, characterized in that it is a dihydrate.

[0071] <Crystal form HyB of belmosudil mesylate> In one embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyB), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0072] (6.6±0.2)°, (16.3±0.2)° and (19.5±0.2)° or (6.4±0.2)°, (6.6±0.2)°, (16.3±0.2)° and (19.5±0.2)° or (6.4±0.2)°, (6.6±0.2)°, (8.1±0.2)°, (16.3±0.2)° and (19.5±0.2)° or (6.4±0.2)°, (6.6±0.2)°, (8.1±0.2)°, (12.9±0.2)°, (16.3±0.2)° and (19.5±0.2)° or (6.4±0.2)°, (6.6±0.2)°, (8.1±0.2)°, (10.2±0.2)°, (12.9±0.2)°, (16.3±0.2)° and (19.5±0.2)° or (6.4±0.2)°, (6.6±0.2)°, (8.1±0.2)°, (10.2±0.2)°, (12.9±0.2)°, (16.3±0.2)°, (19.5±0.2)° and (19.8±0.2)° or (6.4±0.2)°, (6.6±0.2)°, (8.1±0.2)°, (10.2±0.2)°, (12.9±0.2)°, (16.3±0.2)°, (19.5±0.2)°, (19.8±0.2)° and (20.5±0.2)° or (6.4±0.2)°, (6.6±0.2)°, (8.1±0.2)°, (10.2±0.2)°, (12.9±0.2)°, (16.3±0.2)°, (19.5±0.2)°, (19.8±0.2)°, (20.5±0.2)° and (20.9±0.2)°

[0073] In another embodiment, the present invention relates to a Cu-Kα 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyB), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0074] (6.6±0.1)°, (16.3±0.1)° and (19.5±0.1)° or (6.4±0.1)°, (6.6±0.1)°, (16.3±0.1)° and (19.5±0.1)° or (6.4±0.1)°, (6.6±0.1)°, (8.1±0.1)°, (16.3±0.1)° and (19.5±0.1)° or (6.4±0.1)°, (6.6±0.1)°, (8.1±0.1)°, (12.9±0.1)°, (16.3±0.1)° and (19.5±0.1)° or (6.4±0.1)°, (6.6±0.1)°, (8.1±0.1)°, (10.2±0.1)°, (12.9±0.1)°, (16.3±0.1)° and (19.5±0.1)° or (6.4±0.1)°, (6.6±0.1)°, (8.1±0.1)°, (10.2±0.1)°, (12.9±0.1)°, (16.3±0.1)°, (19.5±0.1)° and (19.8±0.1)° or (6.4±0.1)°, (6.6±0.1)°, (8.1±0.1)°, (10.2±0.1)°, (12.9±0.1)°, (16.3±0.1)°, (19.5±0.1)°, (19.8±0.1)° and (20.5±0.1)° or (6.4±0.1)°, (6.6±0.1)°, (8.1±0.1)°, (10.2±0.1)°, (12.9±0.1)°, (16.3±0.1)°, (19.5±0.1)°, (19.8±0.1)°, (20.5±0.1)° and (20.9±0.1)°

[0075] In a further embodiment, the present invention relates to a Cu-Kα ion exchanger having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyB), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0076] (6.4±0.2)°, (6.6±0.2)°, (8.1±0.2)°, (12.9±0.2)°, (15.9±0.2)°, (16.3±0.2)°, (19.5±0.2)°, (19.8±0.2)°, (26.3±0.2)° and (26.4±0.2)°

[0077] In yet another embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyB), characterized in that it has a PXRD containing reflections at the following 2θ angles when measured using radioactive isotropy:

[0078] (6.4±0.1)°, (6.6±0.1)°, (8.1±0.1)°, (12.9±0.1)°, (15.9±0.1)°, (16.3±0.1)°, (19.5±0.1)°, (19.8±0.1)°, (26.3±0.1)° and (26.4±0.1)°

[0079] In yet another embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C.1,2 The present invention relates to a crystalline form of belmosudil mesylate (form HyB), characterized in that it has essentially the same PXRD as that shown in FIG. 4 of the present invention, when measured using radioactive material.

[0080] In another embodiment, the present invention relates to a crystalline form of belmosudil mesylate (form HyB), characterized in that it has a DSC curve comprising an endothermic peak with onset at a temperature of about (75±5)° C., preferably about (75±3)° C., more preferably about (75±1)° C., e.g., 74.7° C., when measured at a heating rate of 10 K / min.

[0081] In a further embodiment, the present invention relates to a crystalline form of belmosudil mesylate as defined in any one of the above embodiments, characterized in that it is a monohydrate (form HyB).

[0082] <Amorphous belmosudil mesylate> The present invention also relates to amorphous belosudil mesylate according to the chemical structure shown in formula (B).

[0083] [ka] In the formula, n is in the range of 0.8 to 1.2, preferably 0.9 to 1.1, even more preferably 0.95 to 1.05, and most preferably n is 1.0.

[0084] In one embodiment, the present invention relates to a Cu-Kα ion exchange membrane having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to an amorphous belmosudil mesylate, characterized in that it has a PXRD which is free of reflections when measured using radiation.

[0085] In yet another embodiment, the present invention relates to a Cu-Kα ion exchanger having a wavelength of 0.15419 nm at a temperature in the range of 20 to 30° C. 1,2 The present invention relates to an amorphous belosudil mesylate, characterized in that it has a PXRD, when measured using radioactive material, essentially the same as that shown in FIG. 5 of the present invention.

[0086] <Pharmaceutical Compositions and Pharmaceutical Uses> In a further aspect, the present invention relates to the use of a crystalline belmosudil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosudil mesylate of the present invention, as defined in any one of the above aspects and their corresponding embodiments, for the preparation of a pharmaceutical composition.

[0087] Furthermore, the present invention relates to a pharmaceutical composition comprising, preferably, an effective and / or predetermined amount of a crystalline belmosudil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosudil mesylate of the present invention, as defined in any one of the above aspects and their corresponding embodiments, and at least one pharma- ceutically acceptable excipient.

[0088] Preferably, the effective amount and / or the predetermined amount of the crystalline belmosudil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosudil mesylate of the present invention defined in any one of the above aspects and their corresponding embodiments is in the range of about 10 to 200 mg calculated as belmosudil. For example, the effective amount and / or the predetermined amount is selected from the group consisting of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg and 200 mg calculated as belmosudil. Preferably, the effective amount and / or the predetermined amount is 200 mg calculated as belmosudil.

[0089] At least one pharma- ceutically acceptable excipient in the pharmaceutical composition of the present invention is preferably selected from the group consisting of fillers, disintegrants, binders, lubricants, glidants, and any combination thereof.Preferably, at least one pharma-ceutically acceptable excipient in the pharmaceutical composition of the present invention is selected from the group consisting of microcrystalline cellulose, hypromellose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and any combination thereof.

[0090] Preferably, the pharmaceutical composition of the present invention is an oral solid dosage form, more preferably a tablet or a capsule. In a particularly preferred embodiment, the pharmaceutical composition of the present invention is a film-coated tablet or a hard gelatin capsule, most preferably a film-coated tablet.

[0091] In another embodiment, the present invention is a film-coated tablet comprising a tablet core and a film coating, wherein the tablet core comprises 200 mg of the crystalline belmosudil mesylate form (e.g., Form I, II, HyA or HyB) of the present invention or amorphous belmosudil mesylate, calculated as belmosudil, as defined in any one of the above aspects and their corresponding embodiments, microcrystalline cellulose, hypromellose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate. In a particular embodiment, the film coating is a non-functional film coating. In another embodiment, the film coating is a polyvinyl alcohol-based film coating. For example, the film coating comprises polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide and iron oxide.

[0092] The pharmaceutical composition of the present invention as defined in any one of the above embodiments may be manufactured by standard manufacturing processes well known to those skilled in the art, e.g. selected from the group consisting of micronizing, blending, milling, granulating (wet or dry granulation), capsule filling, tabletting, film coating and any combination thereof.

[0093] In a further aspect, the present invention relates to a crystalline belmosdil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosdil mesylate of the present invention, or a pharmaceutical composition comprising a crystalline belmosdil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosdil mesylate of the present invention, as defined in any one of the above aspects and their corresponding embodiments for use as a medicament.

[0094] In a still further aspect, the present invention relates to a crystalline belmosdil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosdil mesylate of the present invention, or a pharmaceutical composition comprising a crystalline belmosdil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosdil mesylate of the present invention, as defined in any one of the above aspects and their corresponding embodiments, for use in the treatment and / or prevention of an autoimmune disease.

[0095] In another aspect, the present invention relates to a method for treating an autoimmune disease, comprising administering to a patient in need of such treatment an effective amount of a crystalline belmosdil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosdil mesylate of the present invention, or a pharmaceutical composition comprising a crystalline belmosdil mesylate form (e.g., Form I, II, HyA or HyB) or amorphous belmosdil mesylate of the present invention, as defined in any one of the above aspects and their corresponding embodiments.

[0096] In a preferred embodiment, the autoimmune disease is graft-versus-host disease (GvHD) or systemic sclerosis. In a particularly preferred embodiment, the autoimmune disease is graft-versus-host disease. EXAMPLES

[0097] The following non-limiting examples are illustrative of the present disclosure and should not be construed as limiting the scope of the present invention in any way. Crude vermosudil can be obtained by following the procedure disclosed in Example 82 of WO2006 / 105081A1.

[0098] Example 1: Preparation of belmosudil mesylate form I To a suspension of belmosudil (202.2 mg) in methanol (4 mL) was added methanesulfonic acid (40 μl, 1.4 equivalents). The resulting solution was allowed to stand at room temperature for 4 hours, after which the resulting crystals were collected by filtration and dried first under vacuum (about 5 mbar) at room temperature overnight (about 18 hours), then under vacuum (about 5 mbar) at 65° C. over the weekend to obtain belmosudil mesylate Form I (223.7 mg).

[0099] Example 2: Preparation of belmosudil mesylate form II Belmosudil mesylate form HyA (216 mg, e.g., prepared similarly to the procedure disclosed in Example 3 herein) was annealed on a heat plate at 230°C for 15 minutes and then cooled to room temperature to obtain belmosudil mesylate form II (197 mg).

[0100] Example 3: Preparation of belmosudil mesylate form HyA To a suspension of belmosudil (204.5 mg) in ethanol (4 mL, 75% v / v) was added methanesulfonic acid (40 μl, 1.4 eq.). After stirring the suspension at room temperature for 1 h, the resulting crystals were collected by filtration and dried under vacuum (about 5 mbar) at room temperature for 4 h to obtain belmosudil mesylate form HyA (194.9 mg).

[0101] Example 4: Preparation of belmosudil mesylate form HyB To a suspension of belmosudil (50.0 mg) in ethanol (1 mL, 75% v / v) was added methanesulfonic acid (10 μl, 1.4 equiv.). After the suspension was allowed to stand at room temperature for 1 h, the resulting crystals were collected by centrifugation and dried under vacuum (approximately 5 mbar) at room temperature for 2.5 h to obtain belmosudil mesylate form HyB.

[0102] [Example 5: Preparation of amorphous belmosudil mesylate] To a suspension of belmosudil (50 mg) in water (10 mL), methanesulfonic acid (10 μl, 1.4 eq.) and additional water (5 mL) were added, and the resulting mixture was stirred at room temperature overnight (approximately 18 h). Acetonitrile (8 mL) was added, and the resulting solution was lyophilized to quantitatively obtain amorphous belmosudil mesylate.

[0103] [Example 6: Powder X-ray diffraction] Powder X-ray diffraction was performed on a PANalytical X'Pert PRO diffractometer equipped with a coupled θ / θ goniometer in transmission geometry, a Cu-Kα 1,2 Radiation (wavelength 0.15419 nm) was used with a focusing mirror and a solid-state PIXcel detector. Diffractograms were recorded at a tube voltage of 45 kV and a tube current of 40 mA, applying a 2θ step size of 0.013° with an angular range of 2θ from 2° to 40° at ambient conditions and 40 seconds per step (255 channels). Typical accuracy of 2θ values ​​is in the range of ±0.2° 2θ, preferably ±0.1° 2θ.

[0104] A representative diffractogram of belmosudil mesylate Form I is shown below in Figure 1. The corresponding list of reflections in the 2θ range of 2 to 30° is shown below in Table 1.

[0105] [Table 1]

[0106] A representative diffractogram of belmosudil mesylate Form II is shown below in Figure 2. The corresponding reflection list in the 2θ range of 2 to 30° is shown below in Table 2.

[0107] [Table 2]

[0108] A representative diffractogram of belmosudil mesylate form HyA is shown below in Figure 3. The corresponding reflection list in the 2θ range of 2 to 30° is shown below in Table 3.

[0109] [Table 3]

[0110] A representative diffractogram of belmosudil mesylate form HyB is shown below in Figure 4. The corresponding reflection list in the 2θ range of 2 to 30° is shown below in Table 4.

[0111] [Table 4]

[0112] A representative diffraction pattern of amorphous belosudil mesylate is shown below in Figure 5. As can be seen from Figure 5, amorphous belosudil mesylate does not have any distinct peaks in its powder X-ray diffraction pattern, evidencing the absence of long-range order, which is characteristic of amorphous material.

[0113] [Example 7: Differential scanning calorimetry] DSC was performed on a METTLER Polymer DSC R instrument. Samples (2.89 mg of Form I, 5.18 mg of Form II, 5.33 mg of Form HyA and 5.84 mg of Form HyB) were heated from 25 to 300°C at a rate of 10°K / min in 40 microliter aluminum pans with perforated aluminum lids, respectively. Nitrogen (purge rate 50 mL / min) was used as the purge gas.

[0114] Representative DSC curves of various belmosudil mesylate forms of the present invention are shown in Figures 7-10, and the results are summarized in Table 5 below.

[0115] [Table 5]

[0116] [Example 8: Thermogravimetric analysis] TGA was performed on a METTLER TGA / DSC 1 instrument. Samples (5.15 mg form I, 5.69 mg form II, 3.97 mg form HyA, and 8.55 mg form HyB) were heated from 25 to 300° C. at a rate of 10 K / min, respectively, in 100 microliter aluminum pans closed with aluminum lids. The lids were automatically pierced at the start of the measurement. Nitrogen (purge rate 50 mL / min) was used as the purge gas.

[0117] Representative TGA curves for various belmosudil mesylate forms of the present invention are shown in Figures 11-14, and the results are summarized in Table 6 below.

[0118] [Table 6]

[0119] [Reference Example 1: Preparation of belmosudil HCl according to the procedure disclosed in Example 5 of WO2014 / 055996A1] Belmosudil (215.4 mg) was taken up in 4M HCl in dioxane (4 mL) and stirred at room temperature for 2 hours. The solvent was then removed under vacuum to give belmosudil hydrochloride. The PXRD of the obtained sample is disclosed in Figure 15 below.

[0120] [Reference Example 2: Preparation of belmosudil trifluoroacetate according to the procedure disclosed in Example 92 of WO2008 / 054599A1] A solution of belmosudil (215.2 mg) in TFA (1 mL) and dichloromethane (1 mL) was stirred at room temperature for 1 hour. The solvent was removed under vacuum and diethyl ether (5 mL) was added to the residue. After stirring the mixture for about 20 minutes, the solid was collected by filtration and dried. The PXRD of the obtained sample is disclosed in Figure 16 below.

[0121] [Comparative Example 1: Gravimetric Moisture Sorption] Moisture sorption isotherms were recorded on a SPSx-1μ moisture sorption analyzer (ProUmid, Ulm). The measurement cycle started at 40% ambient relative humidity (RH). The relative humidity was then decreased in 5% steps to 5% RH, followed by further decreases to 3% RH and 0% RH. Afterwards, the RH was increased from 0% to 90% in the sorption cycle and decreased to 0% in 5% steps in the desorption cycle. Finally, the RH was increased from 0 to 40% in 5% steps.

[0122] The time per step was set to a minimum of 2 hours and a maximum of 6 hours. If equilibrium was reached for all test samples within 1 hour prior to the maximum time, with constant mass within ±0.01%, the sequential humidity step was applied prior to the maximum time of 6 hours. If equilibrium was not achieved, the sequential humidity step was applied after the maximum time of 6 hours. The temperature was 25 ±0.1°C.

[0123] The behavior of the various samples in the range 0-80% RH is summarized in Table 7 below.

[0124] [Table 7]

[0125] As can be seen from Table 7, Forms I and II of anhydrous belmosudil mesylate can be designated as slightly hygroscopic, whereas amorphous belmosudil mesylate and belmosudil HCl prepared according to the procedure disclosed in Example 5 of WO2014 / 055996A1 take up significant amounts of water and can therefore be designated as moderately hygroscopic and very hygroscopic, respectively. In contrast, the TFA salt prepared according to the procedure disclosed in Example 92 of WO2008 / 054599A1 shows a significant weight loss of about 13% at 0-80% RH, indicating that an organic solvent is present and is exchanged for water at increasing relative humidity levels. Both hydrates of belmosudil mesylate, Forms HyA and HyB, release water of crystallization only at very low relative humidity, e.g., below 3% RH.

Claims

1. Formula (B): 【Chemical 1】 [wherein, n is 0.8 to 1.2.] Crystals of form HyB of bermodzil mesylate according to the chemical structure shown in, The crystals of form HyB of the bermodzil mesylate have, when measured at a temperature in the range of 20 to 30 ° C using Cu-Kα1,2 radiation having a wavelength of 0.15419 nm, (6.6 ± 0.2) °, (16.3 ± 0.2) ° and (19.5 ± 0.2) ° 2θ angle reflections, crystals having a powder X-ray diffraction pattern.

2. The crystal according to claim 1, having a differential scanning calorimetry curve including an endothermic peak starting at a temperature of (75 ± 5) ° C when measured at a heating rate of 10 K / min.

3. A method for the preparation of a pharmaceutical composition, providing the crystal according to claim 1; providing at least one pharmaceutically acceptable excipient; and obtaining the pharmaceutical composition A method comprising.

4. A pharmaceutical composition comprising the crystal according to claim 1 and at least one pharmaceutically acceptable excipient.

5. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition contains 200 mg of the crystals of bermodzil mesylate according to claim 1 calculated as bermodzil.

6. The pharmaceutical composition according to claim 5, which is an oral solid dosage form.

7. The pharmaceutical composition according to claim 6, wherein the oral solid dosage form is a tablet.

8. The pharmaceutical composition according to claim 7, wherein the tablet is a film-coated tablet.

9. A film-coated tablet comprising a tablet core and a film coating, the tablet core comprising 200 mg of the crystals of bermodzil mesylate according to claim 1 calculated as bermodzil, microcrystalline cellulose, hypromellose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate Film-coated tablets.

10. The crystal according to claim 1, the pharmaceutical composition according to claim 4, or the film-coated tablet according to claim 9 for medical treatment.

11. The crystal according to claim 1, the pharmaceutical composition according to claim 4, or the film-coated tablet according to claim 9 for the treatment of autoimmune diseases.

12. The crystal, pharmaceutical composition, or film-coated tablet for treating an autoimmune disease according to claim 11, wherein the autoimmune disease is graft-versus-host disease (GVHD) or systemic sclerosis.

Images